Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients

Published:2024-09 Issue:5 Volume:85 Page:111088
ISSN:0198-8859
Container-title:Human Immunology
language:en
Short-container-title:Human Immunology

Author:

Sangermano Maria,Negrisolo Susanna^ORCID,Antoniello Benedetta^ORCID,Vadori Marta,Cozzi Emanuele,Benetti Elisa^ORCID

Publisher

Elsevier BV

Reference16 articles.

1. US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States;Johansen;Am J Kidney Dis.,2021

2. Understanding the causes of kidney transplant failure: The dominant role of antibody mediated rejection and non adherence;Sellares;Am J Transplant.,2012

3. Histopathologic Features of Antibody Mediated Rejection: The Banff Classification and Beyond;Cornell;Front Immunol.,2021

4. Treatment of chronic antibody-mediated injury in kidney transplant recipients; a pilot randomized controlled trial;Moreso;Am J Transplant,2018

5. The biology and medical implications of interleukin 6;Tanaka;Cancer Immunol Res,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP